Real‑Time Clinical Trials and the Persistence of Regulatory Record

Jeanette Towles
15 hours ago
4 min read

Real‑time clinical trials are now being discussed by regulators as an operational reality rather than a conceptual experiment. That direction has been developing for some time. In an earlier Synterex blog, we noted that continuous data access would shift the timing and cadence of regulatory engagement without displacing the need for a formal regulatory record. Recent public engagement by the FDA on real‑time trial models reflects that same constraint.

The implication is not that documentation becomes less relevant as data become more visible. It is that documentation must now keep pace with decisions that occur earlier, more frequently, and under conditions of ongoing uncertainty. Real‑time access changes when regulators see information and how sponsors are expected to respond. It does not change the regulator’s reliance on traceable judgment.

This distinction matters for regulatory planning. Some sponsors are interpreting real‑time trial discussions as a signal that traditional documentation expectations will loosen. In practice, expectations are tightening around how decisions are framed, justified, and recorded while a study is still in motion.

Woman in glasses reviews documents under bright skylight in an office. Two men in background focus on their work. Professional mood.

Regulatory Context: What Is Evolving and What Is Not

The FDA’s recent discussion of real‑time clinical trials aligns with a broader move toward lifecycle oversight. Regulators are increasingly open to earlier engagement and ongoing visibility, particularly where technologies enable continuous safety monitoring or adaptive trial conduct.

What remains unchanged is the role of documentation as the authoritative record of intent, interpretation, and accountability. Continuous data streams do not explain why a sponsor acted, delayed action, or chose not to intervene at a particular moment. They do not capture how uncertainty was weighed or which alternatives were considered acceptable at the time.

Regulatory review depends on reconstructing context. In real‑time clinical trials, that reconstruction becomes more complex. There are more interim views, more analytical updates, and more opportunities for divergence between what was visible and what was formally decided. The regulatory record is the mechanism that resolves that ambiguity.

Why the Document Does Not Go Away

Documents serve functions that systems and dashboards cannot replace.

They establish rationale at a specific point in time. They record how available information was interpreted under the governance model in effect at that moment. They provide a stable reference when assumptions, analyses, or data maturity later change.

Real‑time clinical trials increase the number of decision points that carry regulatory significance. Each of those points introduces risk if the sponsor cannot demonstrate how judgment was exercised contemporaneously. Retrospective explanation, unsupported by documentation, is rarely persuasive in a regulatory setting.

For reviewers, the presence of real‑time access does not reduce reliance on documentation. It increases scrutiny of whether emerging information was appropriately contextualized, escalated, and resolved.

Implications for Regulatory Planning

The most material impact of real‑time clinical trials is organizational rather than technical.

Traditional regulatory planning assumes discrete milestones: protocol finalization, interim analysis, database lock, submission. Real‑time models compress and blur those boundaries. Data are visible earlier. Interpretations evolve continuously. Regulatory interaction becomes less episodic and more iterative.

Without deliberate planning, sponsors tend toward extremes. Some attempt to formalize every interim interpretation, generating volume without clarity. Others rely on systems, meetings, and informal alignment, assuming visibility substitutes for record.

Neither approach holds under regulatory scrutiny.

Effective regulatory planning for real‑time clinical trials requires explicit decisions about governance, including:

Which decisions require contemporaneous documentation
How provisional interpretations are distinguished from formal conclusions
How evolving analyses are versioned and contextualized over time
Who is accountable for authoring and approving rationale during trial conduct

These decisions shape the regulatory defensibility of a program long before submission.

Three people in lab coats smiling while using a tablet. They are in a bright office with shelves and binders in the background.

The Reviewer’s Experience in a Real‑Time Environment

Earlier access to data expands the reviewer’s responsibility as well as the sponsor’s. Continuous visibility creates expectations that emerging signals are actively managed and that uncertainty is acknowledged rather than deferred.

Reviewers continue to rely on documentation to understand how thresholds were set, how alternatives were evaluated, and how consistency was maintained across decisions. In real‑time trials, tolerance for post‑hoc narrative that lacks contemporaneous support is limited.

The regulatory record is expected to evolve alongside the data, not be reconstructed after conclusions are reached.

Where AI Can Support Governance

AI is often framed as the enabler of real‑time clinical trials. Its most credible role is in maintaining coherence across fast‑moving workflows.

As data, analyses, and interpretations evolve, misalignment between systems and the regulatory record becomes a persistent risk. AI can help surface inconsistencies, highlight missing rationale, and support version control across documents and

analyses.

Used appropriately, AI supports oversight and foresight. It does not replace regulatory judgment or generate regulatory conclusions. It helps teams recognize when documentation no longer reflects operational reality.

Doctor in a white coat writes on a document while using a laptop. Digital padlocks and papers hover, indicating data security. Blue and gray tones.

Looking Ahead

Real‑time clinical trials will continue to expand as technologies mature and regulatory comfort grows. Sponsors who treat real‑time access as a substitute for documentation will encounter friction. Sponsors who treat it as a catalyst for stronger governance will be better positioned.

The regulatory system remains grounded in record, reason, and responsibility. Real‑time models change the tempo of development. They do not change the need for durable, traceable explanations of how decisions were made.

Related Synterex Insights

Why Reviewers Prioritize Context Over Speed How regulatory decisions depend on traceable rationale rather than rapid data availability.
Hallucinations Aren’t Random What documentation gaps reveal about governance failures in AI‑supported regulatory workflows.

Real‑time Clinical Trials: What Sponsors Should Do Next

Sponsors considering real‑time or near‑real‑time clinical trial models should revisit their regulatory strategies now; reach out to us at Synterex to help. The question is not how quickly information can be shared, but how reliably decisions can be explained later.

That reliability depends on documents that evolve with the trial, reflect judgment as it is exercised, and withstand scrutiny long after the data have moved on.

References